Plain-English translation of NCT06711887 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a long-term follow-up study for people with lupus nephritis (lupus affecting the kidneys) who completed an earlier treatment trial. Researchers are testing , a new medication designed to help control lupus kidney disease. The study will last up to 6 years and will help doctors understand whether people who improve can safely stop the medication, or whether they need to keep taking it.
Lupus nephritis is a serious condition that can lead to kidney damage or failure. While the initial trial showed the new treatment helped some patients, doctors need to know whether improvement lasts after stopping medication, and whether patients who didn't improve initially might benefit from continuing or restarting treatment.
You likely qualify if…
You likely don't qualify if…
If you improved on the medication (achieved remission), you will stop taking it but stay in the study for up to 6 years, visiting the clinic for regular check-ups while taking standard care medications. If you did not improve or switched to open-label treatment in the earlier trial, you will continue receiving the new medication during the extension study. Everyone will be monitored for any sign of flare-ups or safety concerns, and those who stopped the medication can restart it if their disease flares again.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States
Brazil